Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Mansoura Integrated Fertility Center
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01793038CT.gov Clomiphene Citrate Plus uFSH Versus Aromatase Inhibitor Plus uFSH in Clomiphene Resistant Infertile PCOS Women | — | Unknown | — | — | — |
NCT00502229CT.gov Therapy for Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin | — | Withdrawn | — | — | — |
NCT01212263CT.gov Clomiphene Citrate (CC) Co-treatment With HP Urinary FSH vs HP Urinary FSH in CC-resistant PCOS | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Polycystic Ovary Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Urofollitropin (this asset) | Mansoura Integrated Fertility Center | Approved | B · 63 |
| Liraglutide | Peking University Third Hospital | P4 | BBB |
| Human Chorionic Gonadotropin | Eman Basuni Ebrahim Mowad | P4 | BBB |
| Semaglutide | Methodist Health System | P4 | BBB |
| Drospirenone | Ege University | P4 | BBB |
| Follitropin Beta | Universitair Ziekenhuis Brussel | P4 | BBB |
| Ethinyl Estradiol | Ege University | P4 | BBB |
| Glucophage | Near East University, Turkey | P4 | BBB |
| Metformin | Beni-Suef University | P4 | BBB |
+41 more in the Polycystic Ovary Syndrome cohort
Other indications for Urofollitropin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Infertility Disorder | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Urofollitropin in Polycystic Ovary Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/urofollitropin-polycystic-ovary-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →